Greater Cannabis Company Inc (GCAN)

[SPecPrototype]

https://www.healtheuropa.eu/symtomax-the-medical-cannabis-company-leading-the-field/94127/

Symtomax believes that the focus of the major cannabis companies has been on acquiring cannabis production licences rather than cultivation. There is a trend which is seeing American and Canadian companies getting that foothold within the European market and with reliance on the importation of their dry product from another jurisdiction, or even outside of the EU. “There is a clear distribution and revenue cost advantage with cultivating within Europe. The numerous enquiries Symtomax have received for the supply of product, confirms this view,” continued Coetzee.

Symtomax are at the forefront to offer cheaper production, providing products at the certification grade Europe requires. With current demand outstripping supply in the European Union, it’s easy to see why Symtomax are confident about how they have positioned themselves. Symtomax’s vision and strategic direction is evident in the recently announced partnership. In May of this year Symtomax and Greater Cannabis Company a publicly traded biopharmaceutical, based out of Baltimore, with a focus on the development and commercialisation of cannabinoid delivery systems, signed a joint agreement giving rights to use their tested patented delivery products & distribution throughout Europe, Middle East and Africa.

With concern growing over vaping and the numerous incidents now being reported, Symtomax’s new oral patch, provides a safe alternative delivery platform that can be utilised to deliver cannabinoids directly into the body without the harmful side effects of smoking or vaping, and with quicker onset and greater bioavailability than ingestibles.

This new Innovative delivery system using a bio-adhesive, adjustable dose, and fully dissolvable, non-irritant patch, provides for a needle free, intra-oral systemic drug delivery.

Paul Segal, Chairman said: “Our focus has always been on providing safe, accessible, alternative medicines, with patients and consumers demanding safer routes of administration, while achieving proper potency and higher bioavailability, we believe we can now meet this need as well as the expectations.”

Symtomax have established sales and distribution arrangements to supply their cannabinoid-containing products through major pharmaceutical distribution channels throughout Portugal and the European Union (EU). The conveyance technology is designed to accelerate and enhance the delivery and bioavailability of medicines and cannabis actives when compared to traditional methods of enteral administration.